IPCA Laboratories Limited (IPCALAB) — Board Meeting | 26 June 2026 (2 announcements)

The board approved the merger of Krebs Biochemicals & Industries into Ipca Laboratories, subject to regulatory approvals, with an effective date of April 1, 2026. The scheme involves issuing 7 new shares of Re. 1 each for every 200 shares held by Krebs shareholders, resulting in minimal promoter share dilution and a slight public shareholding increase. The merger aims to create operational synergies, secure critical fermentation-based APIs, and reduce administrative burdens, while Krebs' loss-making operations will benefit from Ipca's financial and technical resources.

The board approved the amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories, effective April 1, 2026, following all required approvals. The merger creates operational synergies, consolidates pharmaceutical manufacturing, secures critical API supply, and reduces administrative burdens. Shareholding remains stable with promoters at 44.66% and public at 55.34% post-merger.